Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies-Reference-Cited by-同舟云学术

Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies

Published:2020-06-16 Issue: Volume:11 Page:
ISSN:1664-3224
Container-title:Frontiers in Immunology
language:
Short-container-title:Front. Immunol.

Author:

Zhai Lijie,Bell April,Ladomersky Erik,Lauing Kristen L.,Bollu Lakshmi,Sosman Jeffrey A.,Zhang Bin,Wu Jennifer D.,Miller Stephen D.,Meeks Joshua J.,Lukas Rimas V.,Wyatt Eugene,Doglio Lynn,Schiltz Gary E.,McCusker Robert H.,Wainwright Derek A.

Funder

National Institute of Neurological Disorders and Stroke

National Cancer Institute

Publisher

Frontiers Media SA

Subject

Immunology,Immunology and Allergy

Reference119 articles.

1. Amino acid catabolism: a pivotal regulator of innate and adaptive immunity;McGaha;Immunol Rev.,2012

2. Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond;Platten;Nat Rev Drug Discov.,2019

3. IDO1 in cancer: a Gemini of immune checkpoints;Zhai;Cell Mol Immunol.,2018

4. Molecular pathways: targeting IDO1 and other tryptophan dioxygenases for cancer immunotherapy;Zhai;Clin Cancer Res.,2015

5. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study;Long;Lancet Oncol.,2019

Cited by 149 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of a Compound Inhibiting Both the Enzymatic and Nonenzymatic Functions of Indoleamine 2,3-Dioxygenase 1;ACS Pharmacology & Translational Science;2024-09-12

2. Overexpression of serum HMGB1 and IDO in esophageal squamous cell carcinoma patients: potential clinical auxiliary diagnostic markers and immunotherapeutic targets;Frontiers in Oncology;2024-09-09

3. ACSM2B rs73530508 polymorphism affects susceptibility to esophageal cancer by regulating indolepropionic acid levels;Cancer Pathogenesis and Therapy;2024-09

4. Dual-targeted NAMPT inhibitors as a progressive strategy for cancer therapy;Bioorganic Chemistry;2024-08

5. Peptide-stimulated T cells bypass immune checkpoint inhibitor resistance and eliminate autologous microsatellite instable colorectal cancer cells;npj Precision Oncology;2024-07-29